RD
Reese David M Vice-Président Exécutif, Recherche et Développement
Other M
Insider track record Executive Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the full record of transactions filed by Reese David M, Vice-Président Exécutif, Recherche et Développement. Officer active across 1 company, notably AMGEN INC. Cumulatively, 32 filings have been published. Activity tracked since 30 April 2021. The latest transaction was filed on 2 May 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Reese David M Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations 32 total
● EVP & Chief Technology Officer · Executives · 2 May 2026 · AMGEN INC 746 shares @ US$329.82 0.0001% mcap 2.3% of flow Common Stock SEC:0000318154-26-000067:0
● EVP & Chief Technology Officer · Executives · 2 May 2026 · AMGEN INC 687 shares @ US$329.82 0.0001% mcap 2.1% of flow Common Stock SEC:0000318154-26-000067:1
● EVP & Chief Technology Officer · Executives · 16 Mar 2026 · AMGEN INC 6,022 shares @ US$366.21 18.0% of flow Common Stock SEC:0000318154-26-000032:0
◆ EVP & Chief Technology Officer · Executives · 3 Mar 2026 · AMGEN INC 12,063 shares 0Common Stock SEC:0000318154-26-000021:0
● EVP & Chief Technology Officer · Executives · 11 Nov 2025 · AMGEN INC 6,490 shares 0Common Stock SEC:0000318154-25-000080:0
◆ EVP & Chief Technology Officer · Executives · 6 May 2025 · AMGEN INC 3,549 shares 0Common Stock SEC:0001127602-25-013786:0
● EVP & Chief Technology Officer · Executives · 2 May 2025 · AMGEN INC 702 shares @ US$283.78 1.9% of flow Common Stock SEC:0001127602-25-013533:0
● EVP & Chief Technology Officer · Executives · 2 May 2025 · AMGEN INC 665 shares @ US$283.78 1.8% of flow Common Stock SEC:0001127602-25-013533:1
● EVP & Chief Technology Officer · Executives · 30 Apr 2025 · AMGEN INC 768 shares @ US$288.56 2.1% of flow Common Stock SEC:0001127602-25-013286:0
● EVP & Chief Technology Officer · Executives · 17 Mar 2025 · AMGEN INC 3,635 shares @ US$313.71 11.4% of flow Common Stock SEC:0001127602-25-010060:0
◆ EVP & Chief Technology Officer · Executives · 3 Mar 2025 · AMGEN INC 7,277 shares 0Common Stock SEC:0001127602-25-008428:0
◇ EVP & Chief Technology Officer · Executives · 19 Feb 2025 · AMGEN INC 8,711 shares @ US$156.35 14.2% of flow Common Stock SEC:0001127602-25-006282:0
◆ EVP & Chief Technology Officer · Executives · 7 May 2024 · AMGEN INC 3,196 shares 0Common Stock SEC:0001127602-24-014858:0
● EVP & Chief Technology Officer · Executives · 5 May 2024 · AMGEN INC 633 shares @ US$311.29 2.0% of flow Common Stock SEC:0001127602-24-014512:0
● EVP & Chief Technology Officer · Executives · 2 May 2024 · AMGEN INC 650 shares @ US$277.37 1.8% of flow Common Stock SEC:0001127602-24-014196:0
● EVP & Chief Technology Officer · Executives · 30 Apr 2024 · AMGEN INC 690 shares @ US$276.38 1.9% of flow Common Stock SEC:0001127602-24-013813:0
● EVP & Chief Technology Officer · Executives · 18 Mar 2024 · AMGEN INC 6,202 shares @ US$268.87 16.6% of flow Common Stock SEC:0001127602-24-010858:0
◆ EVP & Chief Technology Officer · Executives · 6 Mar 2024 · AMGEN INC 12,407 shares 0Common Stock SEC:0001127602-24-009247:0
● EVP, Research and Development · Executives · 28 Nov 2023 · AMGEN INC 165 shares 0Common Stock SEC:0001127602-23-028437:0
● EVP, Research and Development · Executives · 5 May 2023 · AMGEN INC 594 shares @ US$231.89 1.4% of flow Common Stock SEC:0001127602-23-015051:0
◆ EVP, Research and Development · Executives · 2 May 2023 · AMGEN INC 3,814 shares 0Common Stock SEC:0001127602-23-014612:0
● EVP, Research and Development · Executives · 30 Apr 2023 · AMGEN INC 666 shares @ US$239.74 1.6% of flow Common Stock SEC:0001127602-23-014157:0
● EVP, Research and Development · Executives · 17 Mar 2023 · AMGEN INC 3,978 shares @ US$234.57 9.6% of flow Common Stock SEC:0001127602-23-010922:0
◆ EVP, Research and Development · Executives · 6 Mar 2023 · AMGEN INC 7,947 shares 0Common Stock SEC:0001127602-23-009495:0
● EVP, Research and Development · Executives · 2 Nov 2022 · AMGEN INC 2,440 shares @ US$272.06 7.3% of flow Common Stock SEC:0001127602-22-024930:0
25 of 32 declarations
Load more (7 remaining) About Reese David M REESE DAVID M is Vice-Président Exécutif, Recherche et Développement. He has 32 filings in total, all with AMGEN INC, and the sampled recent filings cover the period from 2021-05-04 to 2026-05-05. The total buy amount and the total sell amount are both 0, and the most frequent transaction nature is Retenue fiscale.